Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid Tumors
Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.
Benjamin L. Schlechter, MD, on Addressing Unmet Needs in HER2 Positive Solid Tumors
Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.